Edition:
United Kingdom

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

73.59USD
5:45pm GMT
Change (% chg)

$-0.07 (-0.10%)
Prev Close
$73.66
Open
$73.83
Day's High
$74.01
Day's Low
$73.51
Volume
315,658
Avg. Vol
703,548
52-wk High
$84.57
52-wk Low
$23.50

Select another date:

Mon, Dec 3 2018

Photo

GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

LONDON GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion, a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma Walmsley that unnerved investors. | Video

GSK slides after buying cancer firm Tesaro for hefty $5.1 billion

LONDON GlaxoSmithKline has agreed to buy U.S. cancer specialist Tesaro for $5.1 billion (4 billion pounds), a costly investment to rebuild the pharmaceuticals business by new Chief Executive Emma Walmsley that unnerved investors. | Video

UPDATE 3-GSK slides after buying cancer firm Tesaro for hefty $5.1 bln

* GSK shares see biggest daily fall in 10 years (Adds latest shares, termination fee, more on drug competition)

GSK to buy cancer drugmaker Tesaro for $5.1 billion

LONDON, Dec 3 GlaxoSmithKline said on Monday it had agreed to buy U.S. cancer drug specialist Tesaro for $5.1 billion, marking a major biotech investment by the British drugmaker as its seeks to rebuild its pharmaceuticals portfolio.

Drug developer Tesaro explores sale: Bloomberg

Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.

Drug developer Tesaro explores sale - Bloomberg

Nov 16 Cancer drug developer Tesaro Inc is exploring a sale and is working with financial advisers after receiving takeover interest, Bloomberg reported on Friday, citing people familiar with the matter.

Select another date: